Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Kytril As Effective As IV Ondansetron For Chemotherapy Nausea PHILADELPHIA, PA -- February 10, 1998 -- Results from a large multicentre study comparing the effectiveness of oral and intravenous antiemetics (medication that prevents nausea and vomiting associated with chemotherapy) show that a single oral dose of SmithKline Beecham’s Kytril Tablets (granisetron hydrochloride), is as effective as intravenous ondansetron (32 mg) for cancer patients undergoing moderately emetogenic chemotherapy. The study results are published in this month's Journal of Clinical Oncology. "Oral antiemetics are changing the way physicians manage nausea and vomiting associated with chemotherapy,” said lead investigator Edith Perez, M.D., associate professor of medicine, Mayo Clinic, Jacksonville, FL. “We now have clinical evidence that a single dose of Kytril Tablets is as effective as intravenous ondansetron. This is good news because oral antiemetics such as Kytril offer a convenient and cost effective alternative to intravenous antiemetics." In this double-blind, randomized, multicentre trial, 1,085 patients who were not previously treated with chemotherapy received either Kytril Tablets or intravenous ondansetron prior to an initial course of moderately emetogenic chemotherapy (cyclophosphamide or carboplatin). In a double-blind design, half the patients were administered a single oral dose of Kytril (two 1 mg tablets) one hour before chemotherapy; the other half received ondansetron 32 mg as a 15 minute infusion 30 minutes before chemotherapy. Approximately 80 percent of all patients received corticosteroids (dexamethasone or methylprednisolone). The primary endpoint was the proportion of patients in each treatment group who achieved total control of symptoms (no nausea, emesis, or rescue antiemetic therapy) over the 24 and 48 hours following the start of chemotherapy. Secondary endpoints were: proportion of patients in each treatment group who experienced no nausea or need for additional antiemetic therapy over 24 and 48 hours; and proportion of patients in each treatment group who experienced no emesis or need for additional antiemetic therapy over 24 and 48 hours. More information on: Kytril, SmithKline Beecham E-mail this page to a friend or colleague! To print, use this version